دورية أكاديمية
Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
| العنوان: | Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration? |
|---|---|
| المؤلفون: | Caravita, S. |
| المساهمون: | Villani, A., Ravaro, S., Cerea, P., Caravita, Sergio, Ciambellotti, F., Branzi, G., Munforti, C., Parati, G., Malfatto, G. |
| سنة النشر: | 2020 |
| المجموعة: | Aisberg - Archivio istituzionale dell'Università di Bergamo |
| مصطلحات موضوعية: | chronic heart failure, sacubitril, valsartan, ventricular remodeling, Adult, Aged, 80 and over, Angiotensin II Type 1 Receptor Blocker, Drug Combination, Female, Heart Failure, Human, Male, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Neprilysin, Protease Inhibitor, Pulmonary Circulation, Recovery of Function, Retrospective Studie, Stroke Volume, Time Factor, Treatment Outcome, Ventricular Function, Left, Right, Settore MED/11 - Malattie dell'Apparato Cardiovascolare |
| الوصف: | AIMS: The angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan (LCZ696) is recommended for the treatment of patients with heart failure in New York Heart Association (NYHA) class II-III and left ventricular ejection fraction (LVEF) 35% or less. We examined the effects of sacubitril/valsartan on cardiac remodeling and their correlation with heart failure duration in patients enrolled in our heart failure clinic from March 2017 to December 2019. METHODS: Echocardiographic and clinical/laboratory data were collected at baseline and at 6-month and 12-month follow-up visits in 69 patients (age 67 ± 12 years, disease duration 8.4 ± 5.8 years, 93% men). RESULTS: At both time points, mean NYHA class, NT-proBNP level, LVEF, LV end-systolic volume, and estimated systolic pulmonary pressure significantly (P < 0.05) improved versus baseline, as did the proportion of patients with diastolic dysfunction grade 3 or functional mitral regurgitation grade 3-4. In the subgroup with mean disease duration less than 8.5 years (n = 40), there was a significant improvement in all variables at both time points; in this group, a recovery of right ventricular function was also seen at the 12-month follow-up. On the contrary, patients with heart failure duration of at least 8.5 years (n = 29) showed only a slight improvement in LVEF and mitral regurgitation at 12 months. There were no significant changes in renal function and/or potassium levels in all patients. CONCLUSION: In patients with a relatively short disease duration, sacubitril/valsartan was associated with a strong favorable remodeling of the left ventricle and improvement in pulmonary circulation. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | remote |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/32744827; info:eu-repo/semantics/altIdentifier/wos/WOS:000561261800011; volume:21; issue:9; firstpage:682; lastpage:687; journal:JOURNAL OF CARDIOVASCULAR MEDICINE; http://hdl.handle.net/10446/188818Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85089041552 |
| DOI: | 10.2459/JCM.0000000000001000 |
| الإتاحة: | https://doi.org/10.2459/JCM.0000000000001000Test http://hdl.handle.net/10446/188818Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.9274155 |
| قاعدة البيانات: | BASE |
| DOI: | 10.2459/JCM.0000000000001000 |
|---|